Global Osteosarcoma Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2017" report to their offering.

Osteosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 7, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Osteosarcoma - Overview
  3. Osteosarcoma - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Osteosarcoma - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Osteosarcoma - Companies Involved in Therapeutics Development
  • Advaxis Inc
  • Allosteros Therapeutics Inc
  • Amgen Inc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics Inc
  • CorMedix Inc
  • CytRx Corp
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • Intezyne Technologies Inc
  • Isofol Medical AB
  • Johnson & Johnson
  • MacroGenics Inc
  • MD Biosciences GmbH
  • MediaPharma srl
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Novartis AG
  • Oncolys BioPharma Inc
  • Pfizer Inc
  • Shionogi & Co Ltd
  • Teijin Pharma Ltd
  • United Therapeutics Corp

For more information about this report visit http://www.researchandmarkets.com/research/zmr82p/osteosarcoma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs